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Drinking water may contain elevated concen-
trations of arsenic, a well documented potent
toxicant and carcinogen [International Agency
for Research on Cancer (IARC) 2004], lead-
ing to chronic, often lifelong exposure.
Arsenic in the bedrock and mineral deposits
easily dissolves into the surrounding ground-
water, and enhanced levels are found in most
countries. Globally, > 100 million people are
exposed, and Bangladesh is one of the most
severely affected countries. About 10 million
tube wells were installed across Bangladesh in
the last few decades to decrease the use of con-
taminated surface water as drinking water.
Approximately 50% of the tube wells, provid-
ing water to about 57 million people in
Bangladesh, contain arsenic at levels exceeding
the World Health Organization (WHO)
drinking-water guideline of 10 µg/L (British
Geological Survey 2001; IARC 2004). 
There is a wealth of data on arsenic-
related health effects in adults, including vari-
ous forms of cancer, skin lesions, diabetes
mellitus, chronic bronchitis, cardiovascular
disease, peripheral neuropathy, as well as
hematologic, liver, and kidney effects (IARC
2004; National Research Council 2001).
There is also increasing evidence of negative
effects of exposure to arsenic in drinking
water on fetal growth, fetal loss, and infant
mortality (Hopenhayn-Rich et al. 2000;
Huyck et al. 2007; Milton et al. 2005;
Rahman et al. 2007; von Ehrenstein et al.
2006; Yang et al. 2003) as well as neurodevel-
opment in school-age children (Calderon
et al. 2001; Dakeishi et al. 2006; Rosado
et al. 2007; Tsai et al. 2003; Wasserman et al.
2007; Wasserman et al. 2004; von Ehrenstein
et al. 2007), but little is known about the
critical windows of exposure. Generally, the
brain is particularly susceptible to toxic insult
during development (Grandjean and
Landrigan 2006). That may be particularly
true for arsenic that readily crosses the pla-
centa (Concha et al. 1998a) and exerts epige-
netic effects via interactions with DNA
methylation (Reichard et al. 2007) and inter-
acts with multiple nuclear receptors (Bodwell
et al. 2006). Such alterations may also cause
functional changes via altered fetal program-
ming, leading to increased susceptibility to
diseases later in life (Heindel 2007; Vahter
2008). Thus, it is essential to assess exposure
to arsenic early in life. However, the few
available data on postnatal exposure to arsenic
via breast milk are not conclusive. For exam-
ple, indigenous women in the Argentine
Andes exposed to about 200 µg/L arsenic in
the drinking water showed very low excretion
in breast milk (~ 3 µg/L) (Concha et al.
1998b), whereas a Bangladeshi study reported
up to 38 µg/L in breast milk in a small group
of seven women (Watanabe et al. 2003). 
The aim of the present study was to assess
the exposure to arsenic through breast milk in
Bangladeshi infants who live in an area with
elevated arsenic exposure because of arsenic in
tube-well water (Vahter et al. 2006). We ana-
lyzed metabolites of inorganic arsenic (iAs) in
breast milk and urine from 98 3-month-old
infants, with detailed information on breast-
feeding practices and maternal arsenic expo-
sure, as measured by concentrations in blood,
urine, and saliva. Arsenic is metabolized in the
body by methylation, and the main metabo-
lites produced—methylarsonic acid (MA) and
dimethylarsinic acid (DMA)—are readily
excreted in urine (Vahter 2002). Although an
efficient methylation of arsenic to DMA
increases the rate of excretion and is likely to
reduce the health risks (Vahter 2002), the pro-
portion of MA in urine has been associated
with increased risk of a number of different
health effects in adults (Tseng 2007), possibly
because it is related to the intermediate triva-
lent and highly toxic MA (Bredfeldt et al.
2006) in the tissues (Vahter 2002). 
Materials and Methods
Study area and individuals. The study was
carried out in Matlab, about 53 km south-
east of Dhaka, Bangladesh, where the
International Center for Diarrhoeal Disease
Research is running a health and demo-
graphic surveillance system recording all vital
events, as well as a hospital and four health
clinics. Our ongoing research project to eval-
uate effects of arsenic exposure via the drink-
ing water on pregnancy outcome and child
development is nested in a large randomized
population-based food and micronutrient
supplementation trial in pregnancy (the
Maternal and Infant Nutrition Interventions
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BACKGROUND: Chronic arsenic exposure causes a wide range of health effects, but little is known
about critical windows of exposure. Arsenic readily crosses the placenta, but the few available data
on postnatal exposure to arsenic via breast milk are not conclusive.
AIM: Our goal was to assess the arsenic exposure through breast milk in Bangladeshi infants, living
in an area with high prevalence of arsenic-rich tube-well water. 
METHODS: We analyzed metabolites of inorganic arsenic in breast milk and infant urine at
3 months of age and compared them with detailed information on breast-feeding practices and
maternal arsenic exposure, as measured by concentrations in blood, urine, and saliva. 
RESULTS: Arsenic concentrations in breast-milk samples were low (median, 1 µg/kg; range,
0.25–19 µg/kg), despite high arsenic exposures via drinking water (10–1,100 µg/L in urine and
2–40 µg/L in red blood cells). Accordingly, the arsenic concentrations in urine of infants whose
mothers reported exclusive breast-feeding were low (median, 1.1 µg/L; range, 0.3–29 µg/L),
whereas concentrations for those whose mothers reported partial breast-feeding ranged from 0.4 to
1,520 µg/L (median 1.9 µg/L). The major part of arsenic in milk was inorganic. Still, the infants
had a high fraction (median, 87%) of the dimethylated arsenic metabolite in urine. Arsenic in
breast milk was associated with arsenic in maternal blood, urine, and saliva. 
CONCLUSION: Very little arsenic is excreted in breast milk, even in women with high exposure from
drinking water. Thus, exclusive breast-feeding protects the infant from exposure to arsenic.
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6 March 2008]of Matlab; MINIMat), which includes
approximately 4,500 women recruited in
early pregnancy (November 2001 to October
2003) and followed during pregnancy until
6 months postpartum. Urine and blood sam-
ples were collected repeatedly for evaluation
of nutritional status and arsenic exposure, and
breast milk samples were collected at 1, 2, 6,
and 12 months postpartum. We previously
reported that the pregnant women (subgroup
recruited in 2002) showed a wide range of
arsenic concentrations in their urine, largely
reflecting the concentrations in the drinking
water (Vahter et al. 2006).
An additional arm of the MINIMat study
evaluated the effect of exclusive breast-feeding
counseling on the rate and duration of exclu-
sive breast-feeding. To validate the data on
infant feeding practices reported by the
women in questionnaires, a subcohort of
98 pairs of mothers and their 3-month-old
infants was selected from August 2003 to
March 2004 for assessment of breast-milk
and non-breast-milk water intakes using the
dose-to-mother deuterium dilution technique
(Moore et al. 2007). Based on the measure-
ment of deuterium in collected samples of
maternal saliva and infant urine, infant
intakes of breast-milk and non-breast-milk
water were estimated. These data showed
good agreement between actual intakes and
those reported by questionnaire (Moore et al.
2007). We then used residual samples of
infant urine and maternal saliva to evaluate
the exposure to arsenic via breast milk. We
analyzed the concentrations of arsenic
metabolites in the infants’ urine samples and
compared them with those in breast milk,
collected from the mothers at about the same
time. Breast milk samples were available for
79 (81%) of the mothers. Information on
breast-feeding practices was obtained from
the questionnaire concerning exclusivity of
breast-feeding practices. The metabolite pat-
tern in infant urine was compared with that
in maternal urine, collected in early preg-
nancy [gestational week (GW) 8], before the
pregnancy-related change in arsenic metabo-
lism (Concha et al. 1998a).
To evaluate the excretion of arsenic in
breast milk, we compared the milk arsenic con-
centrations with those in maternal saliva, col-
lected at the same time as the infant urine
samples. Because there is no previous informa-
tion on the excretion of arsenic in saliva, we also
measured arsenic concentrations in samples of
maternal blood, collected 3 months later
(6 months postpartum) from 38 (39%) of the
mothers, and maternal urine, collected in late
pregnancy (GW30; n = 91). Usually arsenic
exposure via drinking water is chronic in
nature, resulting in small variations in blood
and urinary arsenic concentrations over time
(Concha et al. 2002). However, we could not
affirm that the maternal blood arsenic con-
centrations decreased over the 3–4 months
between the collection of milk and the collec-
tion of blood and urine, because a parallel miti-
gation program screened the tube wells for
arsenic, increased the awareness of arsenic in the
tube wells, and worked to ﬁnd alternative water
sources for those with elevated arsenic concen-
trations (Jakariya et al. 2007; Rahman et al.
2006). To evaluate potential changes in mater-
nal arsenic exposure, we also measured the con-
centrations of arsenic in blood samples collected
from the studied mothers in early pregnancy
(GW14). The different matrices and sampling
points are shown in Figure 1. 
Sample collection. All samples of urine,
blood, saliva, and breast milk were stored at
–20°C or –70°C until transported frozen by
air to freezers at the Karolinska Institute, and
kept there until analysis. Maternal urine
samples were collected as described previously
for the women enrolled during January
2002–March 2003 (Vahter et al. 2006).
Urine was collected from infants by placing
cotton balls in disposable diapers and waiting
for the infants to pass urine. The diaper was
checked every 15 min and, if dry, clean cot-
ton balls were inserted. If the infant had
passed urine, the cotton balls were removed
using forceps, and the urine was expressed
using a plastic syringe. For the purpose of the
deuterium dilution study, six urine samples
were collected from all participating infants
over a 15-day period (days 0, 1, 3, 4, 13, and
14). At the same time points, a saliva sample
was collected from the mother of each infant,
at least 30 min after consumption of any food
or drink. Samples were collected by asking the
mother to chew on a cotton ball for approxi-
mately 5 min, and then saliva was expressed
using a plastic syringe. For the purpose of the
current analysis, urine samples from each
individual infant and saliva samples from each
mother were pooled to provide a paired sam-
ple for each participating mother–infant pair.
There was little arsenic (< 0.5 µg/L) released
from the cotton ball when extracted with
deionized water or urine. 
In total, 79 of the studied mothers had
collected breast milk 2–3 months (average,
9.5 weeks) postpartum when they visited the
clinics for follow-up. Before milk collection,
the breast was cleansed with water. Usually
milk was collected from one breast while the
other was given to the baby. The mother gen-
tly expressed 10 mL milk into a plastic tube.
If sufﬁcient milk was not expressed from one
breast, the mother tried with the other breast.
The samples were transported in cooling box
to the Matlab hospital laboratory, where they
were labeled and deep-frozen at –70°C.
Venous blood samples were collected in
the health clinics using 5.5 mL Li-Heparin
tube (Sarstedt, Nümbrecht, Germany), trans-
ported to the hospital laboratory for separation
of erythrocytes, which were stored at –80°C,
transported to Sweden, and analyzed for
arsenic at the Karolinska Institute. Saliva was
collected after 5 min of chewing on cotton to
stimulate salivation (Moore et al. 2007). 
Measurements of arsenic concentrations.
Measurements of total arsenic in maternal
breast milk, saliva, and erythrocytes were per-
formed by inductively coupled plasma mass
spectrometry (ICPMS; Agilent 7500ce series)
with an integrated sample introduction system
(Agilent Technologies, Waldbronn, Germany).
Before the ICPMS analysis, breast milk and
erythrocytes were acid digested with 65% con-
centrated suprapur nitric acid (Merck,
Darmstadt, Germany) in microwave-assisted
autoclave (UltraClave; EMLS, Leutkirch,
Germany). For quality control, reference mate-
rial (Seronom Trace Elements Whole Blood
L-1, Lot MR4206; L-2, Lot 0503109; SERO
AS, Billingstad, Norway) with a reference value
of 1.8 ± 0.40 µg/L and 13.2 ± 1.3 µg/L,
respectively. We obtained an average at 2.2
µg/L and 14 µg/L, respectively (n = 17). 
We measured the sum of iAs and the
methylated metabolites, here referred to as
urinary arsenic (U-As), in maternal urine by
hydride generation–atomic absorption spec-
troscopy (HG-AAS) (Vahter et al. 2006).
Separation of the different As metabolites
[As(III), As(V), MA, and DMA] in urine was
performed by a high performance liquid chro-
matography (HPLC) system (Agilent 1100
series system; Agilent Technologies),
equipped with a Hamilton PRP-X100 anion-
exchange column 4.1 × 250 mm (Reno, NV,
USA) and coupled to hydride generation
(HG) and ICPMS. HG is commonly coupled
to the detector to discriminate for organic
arsenic species like arsenobetaine in the urine,
because these species do not form volatile
arsines as iAs and its metabolites do. The
method and the equipment have been
described in detail elsewhere (Lindberg et al.
2007). For quality control, a reference urine
(NIES CRM no. 18; National Institute for
Environmental Studies, Ibaraki, Japan) with a
Fängström et al.
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Figure 1. Sampling points, maternal urine GW8 and GW30, breast milk 2 months (m) postpartum (pp),
maternal saliva and child urine at 3 m pp, and maternal blood 6 m pp.
Time
Maternal urine Maternal urine Breast milk Maternal saliva
Child urine
Maternal blood
GW8 GW30 2 m 3 m pp 6 m ppcertiﬁed DMA concentration of 36 ± 9 µg/L
was analyzed together with the collected urine
samples. The obtained average (± SD) DMA
concentration was 37 ± 1.7 µg/L (n = 5). The
correlation between measured U-As by
HG-AAS and calculated U-As by adding the
different metabolites measured by HPLC–
HG–ICPMS was 0.98 (n = 87), demonstrat-
ing good column recovery. 
To determine the arsenic compounds in
breast milk, we added 10 µL of concentrated
formic acid (Fluka, Buchs, Switzerland) to an
aliquot of 500 µL breast milk to precipitate
the proteins. Thereafter, the samples were
centrifuged for 15 min at 15,000 rpm
(Microliter centrifuge; Hettich, Tuttlingen,
Germany) to separate fat, proteins, and whey.
For the arsenic measurements, the fat layer
was removed and the whey was carefully
transferred into the polypropylene vials sealed
with rubber caps (both from Agilent,
Waldbronn, Germany). The arsenic com-
pounds were determined with an HPLC sys-
tem (Agilent 1100 series system; Agilent
Technologies) coupled to an ICPMS (7500c;
Agilent) equipped with a Babington type neb-
ulizer. The metabolites were separated on a
Hamilton PRP-X100 anion-exchange col-
umn, 4.1 × 250 mm with 20 mM aqueous
ammonium phosphate (NH4H2PO4) solu-
tion at pH 6 [adjusted with ammonium
hydroxide (NH4OH)] at a flow rate of 1.5
mL/min and a column temperature of 40°C.
The injection volume was set to 20 µL. For
signal enhancement, methanol (MeOH) was
pumped to the ICPMS spray chamber as
described elsewhere (Kovaãeviã and Goessler
2005). The signal was recorded at m/z 75
(75As) and m/z 77 (40Ar37Cl, 77Se). To evalu-
ate the data, we used the ICPMS chromato-
graphic software version C.01.00 (Agilent).
The limit of detection was < 0.01 µg/L for
both blood and saliva. For breast milk and
urine it was 0.2 µg/L for As(V) and 0.1 µg/L
for As(III), MA, and DMA. 
To compensate for variations in urine dilu-
tion, we adjusted the arsenic concentrations to
the average speciﬁc gravity (SG), measured by
a digital refractometer (EUROMEX RD 712
clinical refractometer; EUROMEX, Arnhem,
Holland). U-As was adjusted to the overall
mean SG value of 1.003 g/mL in the infant
urine and 1.012 g/mL in maternal urine,
according to U-As × [(1.003 – 1) or (1.012 –
1)]/(measured SG – 1). SG adjustment is
shown to be less inﬂuenced by body size, age,
and arsenic exposure than is creatinine adjust-
ment (Nermell et al. 2008). The SG of saliva
was about the same (1.003–1.004 g/mL) in all
samples, so we did not adjust arsenic concen-
trations in saliva.
Statistical methods. We used Spearman’s
rank correlation analysis to evaluate the
bivariate associations. We performed multiple
regression analysis to evaluate the effect of
the variables U-As, birth weight, and breast-
feeding practice on the distribution arsenic
metabolites. The analyses were performed
with STATISICA 7.1 (Stat Soft, Inc., Tulsa,
OK, USA). A p-value < 0.05 was considered
statistically signiﬁcant.
Ethics. Approval for the MINMat study
and the infant feeding validation study was
obtained from the Ethical Review Committee,
International Center for Diarrhoeal Disease
Research, Dhaka, Bangladesh, and the
Regional Ethical Committee at the Karolinska
Institute. Written informed consent was
obtained from all participating mothers.
Results
The studied infants were on average 14 weeks
old and had a mean body weight of 5.6 kg.
More detailed demographic data are given in
Table 1. The median arsenic concentration in
infant urine, expressed as the sum of the
arsenic metabolites (iAs, MA, and DMA) and
adjusted to the average SG (1.003 g/mL), was
1.2 µg/L (Table 2). The distribution was
skewed with a mean value of 23 µg/L. There
were three urine samples with > 100 times the
median concentration—142, 324, and 1,517
µg/L—whereas the highest among the others
was 29 µg/L. The arsenic concentrations in
urine were significantly lower in the infants
that were exclusively breast-fed (EBF) (median
U-As, 1.1 µg/L; 10th–90th percentiles,
0.27–6.7 µg/L, maximum 29 µg/L), than in
those that were nonexclusively breast-fed
(NEBF, i.e., predominantly or partly breast-fed)
(median U-As, 1.9 µg/L; 10th–90th percentiles,
0.36–140 µg/L, maximum 1,520 µg/L;
p < 0.05). 
The median arsenic concentration in
breast milk was 1.0 µg/kg ranging up to
19 µg/kg (Table 2). There was a significant
association between arsenic in infant urine and
breast milk (rs = 0.64, p < 0.001, n = 79;
Figure 2), although there were some infants
with high concentrations in urine in spite of
low concentrations in breast milk. The arsenic
in the breast milk samples was essentially in
the form of iAs, and mainly As(III). As(V) was
above the detection limit (0.2 µg/kg) in 11 of
79 samples, whereas DMA could be detected
in 38 and MA in 19 breast milk samples.
Generally the arsenic metabolite pattern was
concentration dependent: At low arsenic con-
centrations (≤ 1µg As/L) only As(III) was
observed; at higher arsenic concentrations,
As(III), DMA, MA, and As(V) were found,
but even then the major fraction was iAs. 
As shown in Table 3, the infant urine
contained 8.2% iAs, 2.8% MA, and 87%
DMA (median values). There was no signiﬁ-
cant difference in the distribution of the
arsenic metabolites by sex or socioeconomic
status, but both percent (%)DMA (nega-
tively) and %iAs (positively) were associated
with U-As and birth weight, whereas %MA
was associated (negatively) with U-As and
breast-feeding (p < 0.05). Using multivariate
analysis, with one model for each arsenic
metabolite, we tested whether the distribution
was associated with U-As, birth weight, and
breast-feeding. After excluding the outlier
(U-As, 1,517 µg/L), the models showed that
%DMA was negatively associated with birth
weight (β = –0.23, p < 0.05) and that %MA
was positively associated with NEBF and
birth weight (β = 0.31 and 0.25, respectively;
p < 0.05). No association was seen for %iAs.
The %DMA and %MA in urine were not
associated with current body weight or weight
gain since birth. The highest urinary arsenic
concentration (1,517 µg/L, excluded in the
multivariate model) had 32% MA and only
Infant arsenic exposure via breast milk
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Table 1. Demographic data on the participating
children (n = 98), with 47% girls and 52% boys. 
Characteristic Value Min–Max
Age (weeks) 14 ± 1.4 11–17
Weight (kg) 5.6 ± 0.76 3.3–7.4
Birth weight (g) 2,733 ± 387 1,480–3,553
Gestational week at birth 39 ± 1.8 30–43
Parity 1.6 ± 1.6 0–7
SES [wealth index (%)]a
11 8
22 8
31 7
41 4
52 2
Abbreviations: Max, maximum; Min, minimum. Values are
mean ± SD or percent.
aWealth index was based on information on household
assets and estimated by principal component analysis,
producing a weighted score. 
Table 2. Concentrations of arsenic in infant urine at 3 month of age, breast milk, saliva, and blood, as well as
maternal urine (GW8 and GW30). 
No. Mean Median 10th–90th Min–Max
Infant urine, 3 months (µg/L)a 98 23 1.2 0.27–8.3 0.10–1,520
Breast milk, 2–3 months pp (µg/kg) 79 1.8 1.0 0.38–4.3 0.25–19
Saliva, 3 months pp (µg/kg) 98 2.5 1.3 0.69–6.3 0.51–17
For evaluation of changes over time
Erythrocytes, GW14 (µg/kg) 13 13 9.2 2.6–28 2.3–39
Erythrocytes, 6 months pp (µg/kg) 38 13 5.7 2.8–35 1.8–41
Urine, GW8 (µg/L)b 97 142 49 22–434 12–810
Urine, GW30 (µg/L)b 91 167 67 21–550 10–1,130
Abbreviations: Max, maximum; Min, minimum; pp, postpartum. 10th and 90th are percentiles.
aAdjusted to average SG of 1.003 g/mL. bAdjusted to average SG of 1.012 g/mL.15% DMA. There was no signiﬁcant associa-
tion between %MA or %DMA in infant and
maternal (GW 8) urine. 
We estimated maternal exposure by
arsenic concentrations in urine (GW30),
saliva (3 months postpartum), and erythro-
cytes (6 months postpartum). The arsenic
concentrations in saliva were low (median, ~1
µg/kg), whereas blood and urine contained
median arsenic concentrations at 5.7 and 67
µg/L, respectively, with rather wide variations
(Table 2). Maternal U-As concentrations
were adjusted to the average SG 1.012 g/mL.
As shown in Figure 3, there were significant
correlations between arsenic concentrations in
breast milk and all other maternal biomarkers
of exposure: erythrocytes (rs = 0.71, n = 31; p
< 0.001), saliva (rs = 0.69; n = 79; p < 0.001),
and urine (rs = 0.61, n = 79; p < 0.001). The
correlations between arsenic concentrations in
all the maternal biomarkers are shown in
Table 4. 
Discussion 
The present study is the first to clarify that
the excretion of arsenic in breast milk is
mainly in the trivalent inorganic form (arsen-
ite) and that there is a signiﬁcant association
between arsenic concentrations in milk and
maternal blood. Still, arsenic concentrations
in breast milk were generally low in the stud-
ied rural Bangladeshi women (about 1 µg/kg),
despite high arsenic exposures. Consequently,
the arsenic concentrations in urine from the
EBF infants were low, mostly around 1 µg/L.
This ﬁnding conﬁrms previous reports on low
transfer of arsenic to breast milk in lactating
mothers in other countries (Concha et al.
1998b; Samanta et al. 2007).
Although the 90th percentile of the arsenic
concentrations in urine of EBF infants was 6.7
µg/L, or about 10% of that in maternal urine,
two infants had concentrations > 20 µg/L.
Whether this originated from breast milk or
the child had been given some water or semi-
solid food is not known. Because the breast
milk samples in general were collected a few
weeks before the collection of infant urine, the
mothers might have had an occasional very
high intake of arsenic at the time of the infant
urine collection. Also, we cannot entirely rule
out the possibility that the samples had been
contaminated by arsenic—for example, from
water used for cleansing the infant—although
this would likely have a minor influence on
the concentrations (e.g., the addition of 0.1
mL of water with 500 µg As/L to 10 mL urine
would only increase the concentrations by
5 µg/L). The children with the very highest
arsenic concentrations in urine (142, 324, and
1,517 µg/L), were not exclusively breast-fed,
but were receiving other, complementary
foods (water, other liquids, semisolid foods),
in addition to breast milk. 
We show for the first time that human
breast milk contains almost entirely iAs, mainly
in the trivalent form, which implies that the
infants are exposed mainly to arsenite via breast
milk, although at low doses. As(V) was
detected in 14% of the samples, but we cannot
exclude that some As(III) had been oxidized
after sampling, during transport and storage of
the milk samples. The results indicate that the
methylated arsenic metabolites in blood plasma
do not easily pass over the mammary glands.
Indeed, we found that the arsenic concentra-
tions in breast milk were negatively correlated
with %DMA (rs = –0.19) and positively corre-
lated with %iAs (rs = 0.16) in maternal urine.
Thus, an efﬁcient maternal methylation of iAs
leads to less arsenic excretion in breast milk.
Possibly, As(III), which is the only arsenic
metabolite that is protonated at physiologic
pH (pKa1 of arsenous acid = 9.2), passes via
aquaglyceroporins, which are the main trans-
porters of As(III) in most organisms (Liu et al.
2004; Rosen 2002), and present in the mam-
mary gland during lactation (Matsuzaki et al.
2005). Arsenate is likely to be transported by
the phosphate transporters (Rosen 2002).
Assuming somewhat lower arsenic concentra-
tions in plasma compared with erythrocytes
Fängström et al.
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Table 3. Distribution of arsenic metabolites in infant urine at 3 months of age (n = 98) and maternal urine at
GW8 (n = 97). 
As µg/L %iAs %MA %DMA
All infantsa
Median 1.2 8.2 2.8 87
Mean 23 12 3.8 84
10th–90th 0.27–8.3 0–29 0–8.9 68–100
Range 0.10–1,520 0–60 0–32 15–100
Maternal GW8b
Median 49 14 9.5 77
Mean 142 14 9.8 76
10th–90th 22–430 4.5–24 4.7–16 66–85
Range 12–810 0–39 3.1–22 56–97
Values represent micrograms per liter (% of total arsenic metabolites). 10th and 90th are percentiles.
aInfant U-As was adjusted to SG 1.003 g/mL. bMaternal U-As was adjusted to SG 1.012 g/mL.
Figure 2. Scatterplot between the sum of arsenic metabolites (iAs, MA, and DMA) in urine (µg/L, SG 1.003
g/mL) of 3-month-old infants and the concentrations of arsenic in breast milk (µg/kg) (rs = 0.64, p < 0.001,
n = 79). Inset shows an enlargement of the diagram at the low concentration range. 
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Arsenic in breast milk 2–3 months postpartum (μg/kg)(WHO 2001) and a similar pattern of arsenic
metabolites in blood plasma as in urine at
about 20% iAs (Gamble et al. 2007), the
results indicate a breast milk:plasma ratio of
about one for iAs. This implies no barrier
towards iAs in the mammary gland. 
The present study is also the first to
demonstrate an efﬁcient methylation of iAs in
infants. We observed very high fractions of
DMA in the infant urine (overall median of
87% and 89% in EBF infants). The average
%MA in urine, which is known to be associ-
ated with increased health risks in adults [for
review, see, e.g., Lindberg et al. (2008); Tseng
(2007)], was only 2.8%, (2.3% in EBF infants)
compared with 10% in the studied mothers
and 10–20% in most studied population
groups (Vahter 2002). Similar high %DMA
and even lower %MA were reported for new-
born babies in the Andes, Argentina, which
was related to the efﬁcient arsenic methylation
in late pregnancy, resulting in transfer of
mainly DMA to the fetus before birth (Concha
et al. 1998a). We recently proposed (Vahter
2007) that this high level of arsenic methyla-
tion in pregnant women is a result of the
de novo synthesis of choline by phosphatidyle-
tanolamine methyltransferase, which is up-reg-
ulated in pregnancy to meet the fetal demand
of choline for brain development (Zeisel
2006b). The endogenously produced choline,
via betaine and betainehomocysteine methyl-
transferase, is also the only alternate pathway to
the folate-linked remethylation of homo-
cysteine to methionine, and therefore particu-
larly important in women with low intake of
folate (Velzing-Aarts et al. 2005; Zeisel 2006a),
such as those in the present study (Li et al.
2007). An efﬁcient removal of homocysteine is
a prerequisite for an efficient one-carbon
metabolism, by which arsenic is methylated.
The endogenous maternal synthesis of choline
provides a high level of circulating free choline
in the newborn child (Ilcol et al. 2005), which
may support the methylation of ingested
arsenic. In addition, the folate concentration in
the fetal liver is nearly 50% higher than in the
maternal liver, and contributes to an appropri-
ate metabolic activity in the developing child
(Maloney et al. 2007; Wallace et al. 2008).
Folate in breast milk reaches maximum levels
first some months postpartum (Khambalia
et al. 2006; Monsen et al. 2003), whereas
appreciable amounts of choline are present
already in the ﬁrst mature milk (Holmes et al.
2000; Ilcol et al. 2005) to meet the demand of
choline for the developing brain, as well as a
continuous adequate one-carbon metabolism
and methylation of arsenic, as shown in the
present study. The choline content of human
breast milk doubles during the ﬁrst weeks after
delivery (Holmes et al. 2000), by active uptake
from maternal circulation and de novo synthe-
sis from phosphatidylethanolamine in the
mammary gland (Yang et al. 1988). 
Unexpectedly, birth weight, but not cur-
rent body weight or weight gain, was positively
associated with infant urinary %MA and nega-
tively associated with %DMA. The reason for
this is not known, but possibly it is related to
elevated infant homocysteine levels, a known
risk factor for elevated %MA in urine (Gamble
et al. 2005). Unlike the situation in older chil-
dren and adults, low homocysteine levels in
infants are critically dependent on adequate
vitamin B12 levels, which are related to the
maternal vitamin B12 status (Ueland and
Monsen 2003). There seems to be insufﬁcient
vitamin B12 transfer over the placenta, leading
to low newborn stores, particularly in mothers
with low vitamin B12 status. This was the case
for many of the Matlab women (Li et al. 2007)
as well as many other poor women, especially
with diets low in meat (Allen 2005; Specker
et al. 1990). In addition, a low serum vitamin
B12 level in the mother results in low concen-
tration in breast milk, and still lower vitamin
status and higher homocysteine in the infant.
Probably, high-birth-weight infants have
depleted the maternal vitamin B12 stores to a
larger extent than small infants, both during
the growth spurt in late gestation and post-
natally, as they consume more breast milk. 
The extent to which the observed efﬁcient
arsenic methylation protects against toxic
effects of arsenic exposure during fetal life and
infancy remains to be elucidated. There was a
clear tendency of increasing %MA with
increasing exposure (increasing U-As). The
two infants with U-As concentrations at 140
and 220 µg/L had 6–9% MA and the infant
with > 1,500 µg/L had 32% MA in the urine.
This is most likely attributable to the inhibi-
tion of the arsenic methyl transferase by the
excess iAs. It has previously been shown that
the second methylation step is sensitive to
high concentrations of arsenic (Li et al. 2007;
Lindberg et al. 2008). 
This is the ﬁrst report on arsenic concen-
trations in saliva in relation to blood arsenic.
We can conclude that the concentrations
Infant arsenic exposure via breast milk
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Table 4. Correlation between arsenic concentrations in all the maternal biomarkers, as evaluated by
Spearman rank order correlation test.
Erythrocytes
Breast milk Saliva (6 months pp) U-As GW8 U-As GW30
Breast milk 0.61 0.71 0.48 0.64
Saliva 0.61 0.63 0.56 0.61
Erythrocytes (6 months pp) 0.71 0.63 0.53 0.53
U-As GW8 0.51 0.56 0.63 0.59
U-As GW30 0.64 0.61 0.53 0.59
pp, postpartum.
All correlations are statistically signiﬁcant (p < 0.001).
Figure 3. Scatterplots between arsenic in breast milk (2–3 months postpartum) against (A) arsenic in erythrocytes, 6 months postpartum (rs = 0.71 p < 0.001, n =
31); (B) arsenic in saliva (µg/kg; 3 months postpartum (rs = 0.61, p < 0.001, n = 79); and (C) the sum of arsenic metabolites (iAs, MA, and DMA) in maternal urine
GW30 (SG 1.012 g/mL) (rs = 0.64, p < 0.001, n = 76).
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A B Cwere very low, at a similar level as in breast
milk and about 20% of those in erythrocytes.
Still, the saliva samples might have been
slightly contaminated by arsenic from the cot-
ton used during the sampling. Although there
was a significant correlation between arsenic
in saliva and blood (rs = 0.63), the low con-
centrations of arsenic and the small variation
make salivary arsenic unsuitable as a bio-
marker of exposure. Interestingly, Yuan et al.
(2008) reported much higher concentrations
of arsenic in saliva from Inner Mongolia,
China, and the metabolite pattern was similar
to that in drinking water: essentially iAs. 
The main strengths of this study include
the carefully collected urine from the infants
(six urine samples over 2 weeks from each
child), the validated data on breast-feeding
practices, and the arsenic measurements,
using the highly sensitive ICPMS method,
coupled to HPLC–HG generation to enable
speciation of the arsenic metabolites as meas-
ure of arsenic methylation efficiency in the
infants. The main disadvantages are the col-
lection of maternal samples at different points
in time compared with the collection of
infant urine. However, we believe that the
blood arsenic concentrations in the mothers
did not change much over time. The arsenic
concentrations in erythrocytes collected
6 months postpartum (mean, 16 µg/kg) were
about the same as that in blood collected in
early pregnancy (13 µg/L, paired samples),
which would speak against a change to water
sources with lower arsenic concentrations in
response to the mitigation activities.
Similarly, the median arsenic concentration in
maternal urine in GW30 was similar to that
in the urine collected in early pregnancy.
Thus, we can conclude that the blood col-
lected 3–4 months after the breast milk sam-
ples and the urine collected 4.5 months
before the milk samples represented the
maternal exposure at the time of the infant
study. Our previous study showed an overall
median concentration of 80 µg/L in the urine
of women (n = 1,944) in Matlab during 2002
and ﬁrst months of 2003 (Vahter et al. 2006).
However, the women in the geographic area
B, where the main hospital is located and
where the women in the present study lived,
had 55 µg/L in their urine, similar to levels in
the women included in the present study. 
In conclusion, we have shown that very
little arsenic, mainly as iAs, is excreted in
human breast milk, even in women with high
exposure to arsenic via drinking water. Also,
we found an efficient methylation of the
ingested iAs in the infants. This information is
important from a public health point of view
because it implies that the breast-fed infants,
particularly those who are exclusively breast-
fed, are protected from exposure to arsenic
during this critical period of development.
However, to what extent breast-feeding
decreases the health risks associated with pre-
natal arsenic exposure remains to be eluci-
dated. There is an urgent need for evaluation
of arsenic in infant formula and weaning food
in arsenic-contaminated areas. 
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